Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...

Risperidone, an antipsychotic drug commonly used for severe agitation or aggressive behavior, increases stroke risk in patients with dementia. | Neuroscience ...

BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone ...

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...

A massive UK study of more than 165,000 dementia patients has uncovered troubling new evidence about risperidone, a commonly ...

Risperidone is the only drug of its kind licensed for dementia, but a new study has revealed that it poses a high risk of stroke for all dementia patients—contrary to the previously held belief that t ...

(RTTNews) - Lupin (LUPIN) has received approval from the FDA for its Abbreviated New Drug Application for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and ...

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Medincell (Euronext: MEDCL), ...